跳转至内容
Merck
CN
  • Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome.

Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome.

Pediatric blood & cancer (2014-01-07)
Johann K Hitzler, Wensheng He, John Doyle, Mitchell Cairo, Bruce M Camitta, Ka Wah Chan, Miguel A Diaz Perez, Christopher Fraser, Thomas G Gross, John T Horan, Alana A Kennedy-Nasser, Carrie Kitko, Joanne Kurtzberg, Leslie Lehmann, Tracey O'Brien, Michael A Pulsipher, Franklin O Smith, Mei-Jie Zhang, Mary Eapen, Paul A Carpenter
摘要

We report on 27 patients with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) who received allogeneic hematopoietic cell transplantation (HCT) between 2000 and 2009. Seventy-eight percent of patients received myeloablative conditioning and 52% underwent transplantation in second remission. Disease-free survival (DFS) was 24% at a median of 3 years. Post-transplant leukemic relapse was more frequent than expected for children with DS-ALL (54%) than for non-DS ALL. These data suggest leukemic relapse rather than transplant toxicity is the most important cause of treatment failure. Advancements in leukemia control are especially needed for improvement in HCT outcomes for DS-ALL.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
FK-506 一水合物, ≥98% (HPLC)
USP
他克莫司, United States Pharmacopeia (USP) Reference Standard
Supelco
环孢菌素A 溶液, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®